Precision BioSciences Announces Major Executive Leadership Changes Amidst Advancement of Key Gene Editing Programs
Key Points:
- Precision BioSciences, Inc. (Nasdaq: DTIL) has announced significant changes to its senior leadership team effective August 1, 2026.
- Alex Kelly, previously Chief Financial Officer, has been promoted to the newly created role of Chief Operating Officer (COO). He will now oversee all key customer-facing functions.
- Naresh Tanna, formerly Vice President of Investor Relations and Chief of Staff to the CEO, has been appointed as the new Chief Financial Officer (CFO), succeeding Kelly.
- Other changes include the designation of Cassie Gorsuch, Ph.D., as the sole executive responsible for all research functions as Chief Scientific Officer, and the formal designation of Ms. Burris as Chief Accounting Officer and principal accounting officer.
- The company’s leadership restructuring comes as Precision advances its lead ARCUS platform programs, PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy.
Detailed Analysis:
Precision BioSciences, a clinical-stage gene editing company focused on in vivo gene editing therapies, has initiated a substantial organizational shift at the executive level. These leadership changes are strategically timed as the company progresses toward the next set of clinical milestones for its flagship programs, which target high unmet medical needs in chronic hepatitis B and Duchenne muscular dystrophy.
Executive Leadership Changes:
- Chief Operating Officer Appointment: Alex Kelly will transition from CFO to COO, effective August 1, 2026. His compensation will increase to an annual base salary of \$510,000, with a target annual bonus of 45% of his base salary. This move signals an intent to strengthen operational leadership and customer engagement as Precision approaches critical stages in its clinical development pipeline.
- Chief Financial Officer Appointment: Naresh Tanna, age 45, is promoted to CFO. Tanna will be responsible for financial planning, reporting, investor relations, and corporate communications. His prior experience as VP of Investor Relations and Chief of Staff, and involvement in business intelligence and commercial strategy, positions him as a key driver in corporate strategy execution. His employment agreement details will be available in the upcoming quarterly report (Q3 2026).
- Chief Scientific Officer: Cassie Gorsuch, Ph.D., will now oversee all research functions, consolidating the research leadership under a single executive.
- Chief Accounting Officer: Ms. Burris, a Certified Public Accountant with a BS in Business Administration from West Virginia University, is designated as principal accounting officer and Chief Accounting Officer. No changes to her compensation or employment arrangements are noted.
Shareholder and Price-Sensitive Information:
- The reshuffling of executive roles, especially the creation of the COO position and the appointment of a new CFO, is a pivotal move. It reflects Precision’s strategic focus on operational efficiency, financial discipline, and corporate execution as it advances key gene editing programs. These leadership transitions may affect investor sentiment and could impact share price, especially as the company approaches clinical milestones.
- The company is emphasizing its push towards clinical development for PBGENE-HBV and PBGENE-DMD, which, if successful, could represent significant value inflection points for the share price.
- No material changes to compensation for other executives, and no arrangements or understandings with external parties were disclosed that could create conflicts or additional price-sensitive risks.
Regulation FD Disclosure:
- On July 27, 2026, Precision issued a press release announcing these changes. The information provided in Item 7.01 (including the press release) is not considered “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly referenced.
Forward-Looking Statements:
- The company’s statements regarding leadership transitions, clinical milestones, and operational strategy are forward-looking and subject to risks and uncertainties. Actual results may differ materially, and investors are advised to review the company’s SEC filings for a full list of risk factors.
Potential Impact on Share Price:
- This news is potentially price-sensitive and could move the share price due to the direct connection between executive leadership, clinical program progress, and investor confidence. The focus on advancing high-impact gene editing programs and operational readiness positions the company for potential value creation, but also introduces execution risks.
Investor and Media Contact:
- Naresh Tanna, CFO, [email protected]
Disclaimer:
This article is based on information disclosed in Precision BioSciences’ Form 8-K filed with the SEC dated July 27, 2026. The article contains forward-looking statements that are subject to risks and uncertainties. Investors should consult the company’s latest SEC filings and perform their own due diligence before making any investment decisions. The information does not constitute investment advice.
